FORWARD-FANCT07778836
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Start date changed from estimate of Oct 26, 2026 to Aug 5, 2026
- Site details revised at 3 of 4 sites
Notable Start date pushed from Aug 5, 2026 to Oct 26, 2026 Show 6 more changesShow less
- Eligibility criteria shortened, about 7 words
- Primary endpoints: details revised at 2 of 2 entries
- Study sites: 3 to 4
- Secondary endpoints: details revised at 1 of 1 entry
- Publications: details revised at 20 of 26 entries
- Study description expanded, about 3 words
- Minor Secondary endpoints: details revised at 1 of 1 entryv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from baseline in Upright Stability Score (USS) subscale E of modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
Timeframe: Baseline, Weeks 12, 24, 36, 48, 72
Change from baseline in the total modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
Timeframe: Baseline, Weeks 12, 24, 36, 48, 72
Secondary (1)
Change from baseline in the Clinical Global Impression-Severity (CGI-S) score at Week 72
Arms and interventions
NomlabofuspExperimental
Daily subcutaneous injection of nomlabofusp for 72 weeks
PlaceboPlacebo comparator
Daily subcutaneous injection of placebo for 72 weeks
Drugs: Nomlabofusp, Placebo
Sites
4 sites in 1 country